U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H23N3O
Molecular Weight 225.3305
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESAPRAZOLE

SMILES

O=C(CN1CCNCC1)NC2CCCCC2

InChI

InChIKey=RTFADALJKSFJDZ-UHFFFAOYSA-N
InChI=1S/C12H23N3O/c16-12(10-15-8-6-13-7-9-15)14-11-4-2-1-3-5-11/h11,13H,1-10H2,(H,14,16)

HIDE SMILES / InChI

Molecular Formula C12H23N3O
Molecular Weight 225.3305
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Esaprazole, also known as hexaprazole, was developed in the 1980s as a drug for the treatment of gastric and duodenal ulcers. Esaprazole exerts a dose-dependent cytoprotective effect on the gastric mucosa in man. It was shown to have a dose-dependent antisecretory activity, which was particularly evident on secretion volume and acid output. Esaprazole completed phase II clinical trials with only a few minor side effects being reported, but was shown to be less effective than Cimetidine and Ranitidine at healing ulcers. Esaprazole is a weak sigma opioid receptor and muscarinic acetylcholine receptors M3 and M5 ligand. Esaprazole analogs with many compounds showing neuroprotective properties.

CNS Activity

Curator's Comment: low brain penetration potential

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
27.0 µM [IC50]
Target ID: P08483
Gene ID: 24260.0
Gene Symbol: Chrm3
Target Organism: Rattus norvegicus (Rat)
87.0 µM [IC50]
71.0 µM [IC50]
Conditions
Doses

Doses

DosePopulationAdverse events​
1350 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1350 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1350 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Condition: gastric ulcer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
900 mg single, intravenous
Highest studied dose
Dose: 900 mg
Route: intravenous
Route: single
Dose: 900 mg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: gastrointestinal disorder
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of positive allosteric modulators on single-cell oscillatory Ca2+ signaling initiated by the type 5 metabotropic glutamate receptor.
2009 Dec
Patents

Sample Use Guides

Once a day at doses of 900 and 1350 mg/day
Route of Administration: Oral
Esaprazole prevented cell death in a dose-dependent manner against both glutamate and peroxide-induced cell death in primary culture of cortical neurons, with a 27% and 44% decrease in cell death at concentration 100 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:20:21 GMT 2023
Edited
by admin
on Fri Dec 15 16:20:21 GMT 2023
Record UNII
38QSU0IB5L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ESAPRAZOLE
INN   MI  
INN  
Official Name English
N-CYCLOHEXYL-1-PIPERAZINEACETAMIDE
Systematic Name English
ESAPRAZOLE [MI]
Common Name English
C-63
Code English
1-PIPERAZINYL-4-METHYLENECARBONYLCYCLOHEXYLAMINE
Common Name English
1-PIPERAZINEACETAMIDE, N-CYCLOHEXYL-
Systematic Name English
esaprazole [INN]
Common Name English
EXAPRAZOLE
Common Name English
N-(1-PIPERAZINYLACETYL)CYCLOHEXYLAMINE
Common Name English
HEXAPRAZOLE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29701
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
Code System Code Type Description
INN
4975
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
PUBCHEM
68835
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
EVMPD
SUB06607MIG
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
FDA UNII
38QSU0IB5L
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
ChEMBL
CHEMBL1983100
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
NCI_THESAURUS
C65535
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
MERCK INDEX
m1136
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY Merck Index
MESH
C042123
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
SMS_ID
100000084583
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
EPA CompTox
DTXSID0046147
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
CAS
64204-55-3
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY